Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HTFL US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HTFL US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Heartflow, Inc.(HTFL US)

$56.57+2.173.99%Ext:$55.50-1.071.90%(Pre-Market · 13:22:52 UTC)
ProfileFinancialsChartingShort InterestEmployees

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees

Heartflow, Inc.(HTFL US)

$56.57+2.173.99%Ext:$55.50-1.071.90%(Pre-Market · 13:22:52 UTC)
ProfileFinancialsChartingShort InterestEmployees

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees
Ask AI
Ask AI

Heartflow, Inc. — Company Profile

HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.

Sector
Healthcare
Industry
Medical - Healthcare Information Services
Exchange
UQ
CEO
John Farquhar
Headquarters
San Francisco, CA, US
IPO Date
Aug 7, 2025
Employees
843
Website
www.heartflow.com

Key Metrics

Price
$49.32
Market Cap
$4.25B
Revenue (TTM)
$52.59M
Net Income (TTM)
$-27380000.00
EPS (TTM)
-0.07
P/E (TTM)
-38.04
P/B (TTM)
14.89
Dividend Yield
0.00%
ROE (TTM)
-9.58%
ROA (TTM)
-7.96%
Operating Margin
-41.88%

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.

Website
www.heartflow.com
Location
San Francisco, CA, US
Phone650-241-1221
Employees843
CEOJohn Farquhar
SectorHealthcare
IndustryMedical - Healthcare Information Services
IPO DateAug 7, 2025

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

News

  • AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry2 Nov
  • TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients1 Nov
  • Boston Scientific announces results for third quarter 202628 Oct
  • Heartflow (NASDAQ:HTFL) Insider Campbell Rogers Sells 23,933 Shares of Stock27 Oct
  • Heartflow to Report Third Quarter 2026 Financial Results on November 12, 202619 Oct
  • Heartflow (NASDAQ:HTFL) Sets New 12-Month High – Should You Buy?7 Oct
  • Vikram Verghese Sells 7,579 Shares of Heartflow (NASDAQ:HTFL) Stock20 Sep
  • Heartflow (NASDAQ:HTFL) Reaches New 52-Week High – Still a Buy?20 Sep
  • 12,278 Shares in Heartflow, Inc. $HTFL Bought by Amundi18 Sep
  • John C.M. Farquhar Sells 35,010 Shares of Heartflow (NASDAQ:HTFL) Stock16 Sep
  • HeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week High15 Sep
  • Heartflow (NASDAQ:HTFL) versus American Well (NYSE:AMWL) Financial Analysis11 Sep
  • HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High6 Sep
  • Baron SMID Cap ETF Q2 2026 Portfolio Activity4 Sep
  • Bank of New York Mellon Corp Makes New $19.10 Million Investment in Heartflow, Inc. $HTFL1 Sep
  • BlackRock Inc. Makes New $152.50 Million Investment in Heartflow, Inc. $HTFL29 Aug
  • Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half28 Aug
  • Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference27 Aug
  • HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?20 Aug
  • HeartFlow: An Impressive MedTech Growth Play16 Aug

Key Stats

Trading

Px/Chg 1D$49.32 / +0.84%
Avg Volume1.42M
BetaN/A
Mkt Cap4.25B
FD Mkt Cap4.20B

Float

Shrs Out/Float86.24M / 66.29M
Short Float0.08%
Days to Cover1.74
Stock Repurchased$0.00

Current Valuation

EV4.26B
EV/EBITDA-45.86
EV/Sales22.26
P/B14.89
P/S22.22
FCF Yield-0.75%
ROE-9.58%
ROA-7.96%
Current Ratio5.57

Estimates

P/E-38.04
Est P/E0.00
Est EPS-0.19
Est PEG0.00

Valuation

Metric5Yr AvgMay '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-313.34-471.34-155.35
Price / Sales157.46234.0480.88
Price / Book Value26.5738.2514.89
Price / Free Cash Flow-526.59-920.24-132.95
ENTERPRISE VALUE METRICS
Enterprise Value7,867.911,475.74,260.1
Enterprise Value / Sales157.29233.5881.01
Enterprise Value / EBITDA-342.71-514.47-170.95
Enterprise Value / EBIT-311.57-467.40-155.74

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue42.1%87.2125.8176.0
Gross Income52.6%58.194.4135.2
EBITDA21.7%-62.8-65.5-93.1
EBIT20.2%-70.4-73.6-101.7
Net Income10.5%-95.7-96.4-116.8
EPS (Diluted)-59.4%-1.94-1.53-0.32
BALANCE SHEET
Cash & ST Inv20%122.851.4176.8
Total Assets39.4%185.1118.7359.5
Total Liabilities-75.3%962.6978.258.8
Total Shareholder Equity—-777.6-859.5300.6
CASH FLOW
Net Operating Cash Flow-15.9%-76.4-69.0-54.0
Cap Ex-9.3%-6.1-4.4-5.0
Free Cash Flow-15.4%-82.5-73.4-59.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)56.71
Basic Shares86.24
Market Cap4,890.7
Diluted Shares368.54
Fully Diluted Shares Outstanding368.54
Fully Diluted Market Cap20,899.8
+Consolidated Debt26.3
−In-the-Money Convertible Debt—
+Capital Leases6.4
+Operating Leases—
−Cash & Equivalents-19.7
−Short-term Investments-138.6
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value4,897.4

Segment data

Revenue

by Geography

  • Non Us100%

Related companies

BrightSpring Health Services, Inc.

BTSG US

Pro Medicus Ltd./ADR

PMCUF US

Hinge Health, Inc.

HNGE US

Alibaba Health Information Technology Limited/ADR

ALBBY US

Doximity, Inc.

DOCS US

Privia Health Group, Inc.

PRVA US

Winning Health Technology Group Co., Ltd.

300253 CS

JMDC Inc.

4483 JT

Indegene Limited

INDGN IB

Certara, Inc.

CERT US

Pennant Group, Inc.

PNTG US

U S Physical Therapy Inc /NV

USPH US

Heartflow, Inc. — Company Profile

HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.

Sector
Healthcare
Industry
Medical - Healthcare Information Services
Exchange
UQ
CEO
John Farquhar
Headquarters
San Francisco, CA, US
IPO Date
Aug 7, 2025
Employees
843
Website
www.heartflow.com

Key Metrics

Price
$49.32
Market Cap
$4.25B
Revenue (TTM)
$52.59M
Net Income (TTM)
$-27380000.00
EPS (TTM)
-0.07
P/E (TTM)
-38.04
P/B (TTM)
14.89
Dividend Yield
0.00%
ROE (TTM)
-9.58%
ROA (TTM)
-7.96%
Operating Margin
-41.88%

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.

Website
www.heartflow.com
Location
San Francisco, CA, US
Phone650-241-1221
Employees843
CEOJohn Farquhar
SectorHealthcare
IndustryMedical - Healthcare Information Services
IPO DateAug 7, 2025

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

News

  • AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry2 Nov
  • TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients1 Nov
  • Boston Scientific announces results for third quarter 202628 Oct
  • Heartflow (NASDAQ:HTFL) Insider Campbell Rogers Sells 23,933 Shares of Stock27 Oct
  • Heartflow to Report Third Quarter 2026 Financial Results on November 12, 202619 Oct
  • Heartflow (NASDAQ:HTFL) Sets New 12-Month High – Should You Buy?7 Oct
  • Vikram Verghese Sells 7,579 Shares of Heartflow (NASDAQ:HTFL) Stock20 Sep
  • Heartflow (NASDAQ:HTFL) Reaches New 52-Week High – Still a Buy?20 Sep
  • 12,278 Shares in Heartflow, Inc. $HTFL Bought by Amundi18 Sep
  • John C.M. Farquhar Sells 35,010 Shares of Heartflow (NASDAQ:HTFL) Stock16 Sep
  • HeartFlow's CEO Sells 38,900 Shares for $1.8 Million After the Stock Hit a 52-Week High15 Sep
  • Heartflow (NASDAQ:HTFL) versus American Well (NYSE:AMWL) Financial Analysis11 Sep
  • HeartFlow CFO Dumps Over 33,000 Shares for $1.7 Million as the Stock Hits a 52-Week High6 Sep
  • Baron SMID Cap ETF Q2 2026 Portfolio Activity4 Sep
  • Bank of New York Mellon Corp Makes New $19.10 Million Investment in Heartflow, Inc. $HTFL1 Sep
  • BlackRock Inc. Makes New $152.50 Million Investment in Heartflow, Inc. $HTFL29 Aug
  • Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half28 Aug
  • Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference27 Aug
  • HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?20 Aug
  • HeartFlow: An Impressive MedTech Growth Play16 Aug

Key Stats

Trading

Px/Chg 1D$49.32 / +0.84%
Avg Volume1.42M
BetaN/A
Mkt Cap4.25B
FD Mkt Cap4.20B

Float

Shrs Out/Float86.24M / 66.29M
Short Float0.08%
Days to Cover1.74
Stock Repurchased$0.00

Current Valuation

EV4.26B
EV/EBITDA-45.86
EV/Sales22.26
P/B14.89
P/S22.22
FCF Yield-0.75%
ROE-9.58%
ROA-7.96%
Current Ratio5.57

Estimates

P/E-38.04
Est P/E0.00
Est EPS-0.19
Est PEG0.00

Valuation

Metric5Yr AvgMay '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-313.34-471.34-155.35
Price / Sales157.46234.0480.88
Price / Book Value26.5738.2514.89
Price / Free Cash Flow-526.59-920.24-132.95
ENTERPRISE VALUE METRICS
Enterprise Value7,867.911,475.74,260.1
Enterprise Value / Sales157.29233.5881.01
Enterprise Value / EBITDA-342.71-514.47-170.95
Enterprise Value / EBIT-311.57-467.40-155.74

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue42.1%87.2125.8176.0
Gross Income52.6%58.194.4135.2
EBITDA21.7%-62.8-65.5-93.1
EBIT20.2%-70.4-73.6-101.7
Net Income10.5%-95.7-96.4-116.8
EPS (Diluted)-59.4%-1.94-1.53-0.32
BALANCE SHEET
Cash & ST Inv20%122.851.4176.8
Total Assets39.4%185.1118.7359.5
Total Liabilities-75.3%962.6978.258.8
Total Shareholder Equity—-777.6-859.5300.6
CASH FLOW
Net Operating Cash Flow-15.9%-76.4-69.0-54.0
Cap Ex-9.3%-6.1-4.4-5.0
Free Cash Flow-15.4%-82.5-73.4-59.0

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)56.71
Basic Shares86.24
Market Cap4,890.7
Diluted Shares368.54
Fully Diluted Shares Outstanding368.54
Fully Diluted Market Cap20,899.8
+Consolidated Debt26.3
−In-the-Money Convertible Debt—
+Capital Leases6.4
+Operating Leases—
−Cash & Equivalents-19.7
−Short-term Investments-138.6
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value4,897.4

Segment data

Revenue

by Geography

  • Non Us100%

Related companies

BrightSpring Health Services, Inc.

BTSG US

Pro Medicus Ltd./ADR

PMCUF US

Hinge Health, Inc.

HNGE US

Alibaba Health Information Technology Limited/ADR

ALBBY US

Doximity, Inc.

DOCS US

Privia Health Group, Inc.

PRVA US

Winning Health Technology Group Co., Ltd.

300253 CS

JMDC Inc.

4483 JT

Indegene Limited

INDGN IB

Certara, Inc.

CERT US

Pennant Group, Inc.

PNTG US

U S Physical Therapy Inc /NV

USPH US